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NATIONAL INSTITUTES OF HEALTH LUNG FUNCTION SCORE AS A POTEN-
TIAL MARKER FOR THE DEVELOPMENT OF CHRONIC GRAFT-VERSUS-
HOST DISEASE
Walter, E.C.1,2, Vigorito, A.1, Campregher, P.V.1, Martin, P.1,
Flowers, M.1, Chien, J.W.1,2 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Washington School of Medicine, Seattle, WA
Background: The NIH has recommended lung function be mon-
itored using a lung function score (LFS) to diagnose and monitor
chronic graft-versus-host disease (GVHD) of the lung following he-
matopoietic cell transplantation (HCT). However, the relationship
between posttransplant lung function and GVHD has not been
rigorously analyzed.
Methods: We performed a retrospective analysis of 1650 patients
who underwent allogeneic HCT from January 1992 to December
2004 and received pulmonary function testing (PFT) within
60–120 days after transplant (day 80 PFT). The primary exposure
was lung function score and primary outcome a diagnosis of chronic
GVHD in the year following day 80 PFT. Post transplant FEV1,
FVC, TLC, and DLCO were categorized as $ 80, 70–79, 60–69,
and\ 60% predicted. Lung function score (range 2–12) was calcu-
lated using FEV1 and DLCO and then categorized (1–3) according
to NIH recommendations. Chronic GVHD was diagnosed accord-
ing to current NIH guidelines. Cox proportional hazards were calcu-
lated to assess for the relationship between lung function and the
development of chronic GVHD.
Results: There was a stepwise increase in risk of developing
chronic GVHD with each categorical increase in LFS. The risk
of developing chronic GVHD was 1.5 and nearly 3-fold higher
for patients in the LFS categories representing the most severe
lung function [LFS category 2 hazard ratio (HR), 1.46 (95% CI
1.10–1.95); category 3 HR 2.75 (1.00–7.59)]. A similar effect
was seen for FEV1, FVC, and DLCO but not TLC. After adjust-
ment, risk estimates remained largely unchanged. Models using
individual PFT parameters performed similar to models using
LFS categories as judged by c-statistic calculations. At one year
following PFT, there was no difference in the proportion of pa-
tients diagnosed with chronic GVHD depending on LFS cate-
gories. However, the time to a diagnosis of chronic GVHD was
shorter for those patients with the most severe lung function (me-
dian days until diagnosis, 34 for LFS category 3 vs. 126 for LFS
category 0).
Summary: Poor lung function 80 days post allogeneic HCT is
associated with an increased risk of developing chronic GVHD
within the year following PFT. When assessing posttransplant
lung function, FEV1 alone appears to perform as well as the
LFS. These data suggest that routine PFTs following transplant
may help identify patients at higher risk for chronic GVHD and
may allow for earlier interventions to prevent or decrease post-
transplant complications.
Association between lung function score and the subsequent
development of chronic GVHD
LFS category Chronic GVHD (%) Unadjusted HR (95% CI) p-value0 270 (42) Referent -
1 269 (42) 1.07 (0.91-1.27) 0.425
2 59 (45) 1.46 (1.10-1.95) 0.009
3 5 (45) 2.75 (1.00-7.59) 0.050Definition of abbreviations: HR5 hazard ratio; CI5 confidence interval.
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IN VIVO MODULATION OF T CELL AND MONOCYTE FUNCTION FOLLOW-
ING INFUSION OF MESENCHYMAL STROMAL CELLS (MSC)
Castilla-LLorente, C.1,2, Mielcarek, M.1, Iwata, M.1, Abrams, V.K.1,
Hwang, B.1, Nash, R.A.1, Torok-Storb, B.1 1Fred Hutchinson Cancer Re-
search Center, Seattle, WA; 2Hospital Morales Meseguer, Murcia, Spain
Mesenchymal stromal cells (MSCs) expanded ex vivo from aspi-
rated marrow, have been used clinically with variable success. While
it is now generally acknowledged that these benefits are not the result
of engraftment and differentiation of MSC into the target tissues, themechanism by which these beneficial effects are achieved is not clear.
We hypothesize that MSCs mediate their effect by activating an en-
dogenous cell population which in turn modulates the immune re-
sponse and/or homes to damaged tissue and participates in repair.
To test this hypothesis immortalized and cloned populations of ca-
nine MSC were generated to provide a consistent product for in
vivo testing. We evaluate one line, DS-1, by infusion into two normal
dogs. Blood samples were taken pre and immediately post infusion
and at 1, 6, 24, 48, 72, 96 hours, and weekly till day 28. Following
infusion there was no consistent change in the number of WBC,
however by day 3 there was a marked decrease in the % of CD31
cells expressing FOXP3 and TGFb in the blood, which did not re-
cover to pre-infusion levels during the period of observation. At au-
topsy there was an increased number of these cells in the lymph
nodes and spleen, whereas there was an overall decrease in the num-
ber of TH1 cells in these tissues. Quantitative RT- PCR analysis of
cDNA prepared from blood mononuclear cells indicated an upregu-
lation in the expression of CD133, Tie-2, and MARCO between 1–
24 hours post infusion, and an increase in LOX1/OLR1 between 2–4
days. However the % of monocytes and the expression levels of
CD14, CD68, CD45, and CD105/Endoglin were constant at all
time points. Samples taken post infusion were also analyzed for the
presence of DS-1 cells by PCR and in vitro out growth assays.
Results indicated that the DS-1cells were detectable up to 6 hours
post infusion, but not thereafter. Adherent cells grown from blood
mononuclear cells at days 4 and 7, displayed macrophage and endo-
thelial cell morphologies. RT-PCR analysis of these cultures de-
tected expression of macrophage associated markers CD141/
CD681/MARCO1/LOX11, and endothelial cell associated
markers CD341/CD144/VECAD1. These data indicate that a sin-
gle infusion of DS-1 cells results in activation of circulating mono-
cytes and a shift of regulatory T cells from the periphery to lymph
nodes and spleen which persists for at least 28 days. We speculate
that these changes may contribute to the immunomodulatory effects
reported for some preparations of MSC.35
CO-TRANSPLANTATION OF CORD BLOOD WITH WHARTON’S JELLY
DERIVED UMBILICAL CORD – MESENCHYMAL STEM CELL S (UC-MSC)
IMPROVES SHORT TERM MYELOID ENGRAFTMENT INTO NOD/SCID/IL-
2RGNULL MICE
Paganessi, L.A., Walker, A.L., Fung, H.C., Christopherson, K.W. Rush
University Medical Center, Chicago, IL
Hematopoietic stem cells (HSC) are routinely obtained from bone
marrow, mobilized peripheral blood, and umbilical cord blood (CB).
Adult bone marrow has been traditionally utilized as the preferred
source of mesenchymal stem cells (MSC) to provide the stromal com-
ponent necessary to fulfill the requirement of the stem cell niche,
thereby preserving the microenvironment for HSC function. Bone
marrow-derived MSC (BM-MSC) have been shown to maintain the
growth of CB HSC ex vivo and promote engraftment into immunode-
ficient mice. However, the use of a BM-MSC as a feeder layer to sup-
port ex vivo culture and/or hematopoietic stem cell transplantation
(HSCT) of CB may not be the most ideal scenario for the clinical
transplant setting. Recently, MSC obtained from the Wharton’s Jelly
of the umbilical cord (UC-MSC) were shown to have mesenchymal
stem and/or progenitor cell potential as well as secrete several impor-
tant cytokines and growth factors. Having shown in our lab that UC-
MSC exhibit important functional characteristics of stromal cells,
such as the ability to support the maintenance of CB CD341 cells in
long term culture-initiating cell (LTC-IC) assays, we further hypoth-
esized that UC-MSC are able to promote engraftment of CB. To test
this hypothesis, we evaluated the effect of UC-MSC co-transplanta-
tion in the Non-Obese Diabetic/Severe Combined Immunodeficient
/IL-2 Receptor gnull (NOD/SCID/IL2Rgnull) mouse model of
HSCT. We report here that co-transplantation of CB with UC-
MSC resulted in an increase in the percentage of short term repopulat-
ing cells in the bone marrow of sub-lethally irradiated mice three
weeks post transplant. Specifically, increases in the percentage of
CD451 cells from 5.061.0% to 7.860.8% and from 1.160.5% to
11.161.7% were noted for CD341 and MNC recipient mice respec-
tively. In addition, statistically significant increases in the percentage
of CD341, CD341CD38-, CD341CD381, CD331, CD611, and
